Novel combinations and immune therapy using the same
TCR-T cell therapy combined with mRNA treatment effectively targets intracellular PRAME proteins, addressing the limitations of current therapies by enhancing immune response and treating cancers like melanoma and PRAME-positive tumors.
Patent Information
- Application Number
- PCT/US2025/053110
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-04-24
- Filing Date
- 2025-10-29
- Publication Date
- 2026-05-28
AI Technical Summary
Current cancer therapies, such as chimeric antigen receptor (CAR)-T cell therapy and antibody-based approaches, are limited in targeting intracellular proteins, while there is a high unmet need for effective therapeutics that specifically target intracellular proteins highly specific to cancer cells, particularly those expressing the Preferentially Expressed Antigen of Melanoma (PRAME).
A combination therapy involving TCR-T cell therapy and mRNA treatment is administered, where TCR-T cells specifically bind to the PRAME antigenic peptide, and mRNA encoding a PRAME antigenic peptide concatemeric polypeptide is used, including 5’ UTR, 3’ UTR, nucleotide cap, and poly A tail, to enhance immune response against cancer cells.
The combination therapy significantly increases the targeting of intracellular PRAME proteins, inducing a robust immune response and effectively treating proliferative diseases like cancer, including melanomas and other PRAME-positive tumors.